China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
This article was originally published in PharmAsia News
Executive Summary
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.